BACKGROUND: HEPSIN (HPN) gene is one of the most consistently overexpressed genes in patients with prostate cancer; furthermore, there is some evidence supporting an association between HPN gene variants and the risk of developing prostate cancer. In this study, sequence variants in the HPN gene were investigated to determine whether they were associated with prostate cancer risk in a Korean study cohort. METHODS: We evaluated the association of 17 single-nucleotide polymorphisms (SNPs) in the HPN gene with prostate cancer risk and clinical characteristics (Gleason score and tumor stage) in Korean men (240 case subjects and 223 control subjects) using unconditional logistic regression. RESULTS: The statistical analysis suggested that three SNPs (rs45512696, rs2305745, rs2305747) were significantly associated with the risk of prostate cancer (odds ratio (OR) ¼ 2.22, P ¼ 0.04; OR ¼ 0.73, P ¼ 0.03; OR ¼ 0.76, P ¼ 0.05, respectively).
INTRODUCTION
Prostate cancer is one of the most common malignancies described among men in western countries. 1 Similarly, in Korea, the incidence rate of prostate cancer has rapidly increased during the last decade. 2 The etiology of prostate cancer is largely unknown, although several risk factors, such as ethnicity, family history and age, have been strongly associated with an increased risk in patients. 3 Studies of the genetic influences on prostate cancer have indicated that there are familial genes that account for only a small fraction of the genetic components of prostate cancer. Many investigators have investigated the association of singlenucleotide polymorphisms (SNPs) in candidate genes with an increased risk in prostate cancer. The types of candidates include genes in steroid metabolism, oxidative stress, DNA repair, common variants of genes found by family studies, and so on. 4 Hepsin is a type II, integral membrane, serine protease that has been found to be one of the most consistently upregulated genes in patients with prostate cancer. 5 Studies have reported evidence of a strong link between the overexpression of hepsin and prostate cancer tumors. 6--8 The physiological function of hepsin remains unknown, but within the carcinogenetic pathway of the prostate, it appears to have a role in cancer cell migration/invasion, rather than cell proliferation. In probasin promoter-driven hepsin (PB-hepsin) transgenic mice, it has been shown that overexpression of hepsin in the mouse prostate epithelium results in disorganization of the basement membrane and weakening of the epithelial--stromal adhesion. 9, 10 To further explore the potential function of hepsin in prostate cancer progression, PB-hepsin transgenic mice were crossed with mice that expressed the SV40 large T antigen in their prostates (LPB-Tag mice, line 12T-7F). LPB-Tag mice are characterized by a high level of high-grade prostatic intraepithelial neoplasia lesions and preserved prostate structure. Over 55% of the double transgenic LPB-Tag/PB-hepsin mice developed prostate cancer that metastasized to their bones, liver and lungs, whereas single transgenic LPB-Tag or PB-hepsin mice remained free of metastasis. 9, 10 Furthermore, antibodies that neutralize hepsin protease activity have been shown to inhibit cell invasion, but do not affect cell proliferation in prostate cancer cell culture models.
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Hepsin germline variants could potentially change gene expression profiles and alter protein function, which could affect either the risk of developing prostate cancer or the likelihood of progressing to a comparatively more aggressive disease that results in tumor metastasis or death. Hepsin is most likely to have an effect on the progression of prostate cancer in the early stages of the disease, during which the protein 'promotes' PIN lesions to localized prostate cancer. Human cDNA microarray profiling studies have shown hepsin expression is strongest in high-grade prostatic intraepithelial neoplasia lesions, moderate to strong in localized prostate cancer, and weak in metastasized and hormonerefractory lesions. 12 A linkage study of affected brothers identified a locus on chromosome segments 19q12--q13.11, where the HEPSIN (HPN) gene is located, that could be linked to disease aggressiveness. 13, 14 Further work by Pal et al. 15 identified five HPN SNPs that exhibited significant differences in allelic frequencies between prostate cancer cases and healthy controls.
To investigate the potential associations between HPN genetic variations and prostate cancer risk or progression, we conducted a case--control study in Korean men. To capture the underlying genetic variation of HPN, we selected seventeen SNPs spanning the whole gene.
MATERIALS AND METHODS

Study population and blood samples
The blood samples used for this study were obtained from the Korea Prostate Bank (Seoul, Korea). Both prostate cancer and BPH groups originated from a population of older men treated for urological problems at the St Mary's Hospital (Seoul, Korea) and were predominantly of Korean ancestry. Peripheral blood leukocyte samples were obtained for genotyping from 463 men (prostate cancer ¼ 240; BPH ¼ 223) and stored at À80 1C. Subjects with BPH (n ¼ 223) had no sign of prostate malignancy based on PSA blood tests and digital rectal examination of the prostate at the time the samples were taken. The median age of the BPH cohort was 70.5 years and that of the prostate cancer cohort was 69.0 years. BPH samples were used as the control group for several reasons; first, most males have evidence of BPH by the age of 70 or 80 years, so the presence of some degree of BPH is 'normal' at the median age at diagnosis in our prostate cancer cohort (69.0 years). Truly 'normal' samples would thus only be obtained in a much younger control cohort, which could introduce bias. Second, as collection of blood sample requires hospital visiting and a prostate cancer screening procedure of patients, which would only be undertaken in subjects with evidence of symptoms of prostate enlargement. Written informed consent was obtained from all the study participants. The study was approved by the Institutional Review Board of Chung-Ang University Hospital and the Catholic University Hospital (IRB no. C2008035 and CUMC09U092, respectively).
Blood samples were collected in tubes containing sodium EDTA from St Mary's Hospital in Korea. The QIAamp blood extraction kit (Qiagen, Seoul, Korea) was used for the DNA extraction. The Gleason score was classified as low (Gleason score, 2--6), intermediate (4 þ 3, 3 þ 4), or high (8--10) grade. The clinical and pathological regional stages were categorized as localized (T1 or T2N0M0), locally advanced (T3 or T4N0M0) and metastatic (T Â N þ or M þ ), based on pathological and/or radiological reports. Clinical characteristics of studied cases are shown in Table 1 , which displays similar results with the previous Korean study. 16 
SNP selection and genotyping
In this study, we selected 17 SNPs from two international databases (International HapMap and NCBI dbSNPs). Tagging SNP selection are shown in Figure 1 . Briefly, we collected all genotypes from the Han Chinese and Japanese population in the HPN gene region using HapMart of the International HapMap database (version: release no. 27; http://www. hapmap.org) and calculated mean allele frequency and linkage disequilibrium (LD) using Haploview software (Cambridge, USA; http:// www.broad.mit.edu/mpg/haploview), and selected SNPs which have mean allele frequency40.05 and LD40.98. We added more SNPs from NCBI dbSNPs in the HPN gene region. These SNPs were preferred: SNPs that are located in exons or SNPs that lead to amino acid change or non-synonymous SNPs. Genotyping was performed at the multiplex level using the Illumina Golden Gate genotyping system (Illumina, San Diego, CA, USA). 17 Briefly, approximately 250 ng genomic DNA extracted from the blood of each individual was used to genotype each sample that underwent DNA activation, binding to paramagnetic particles, hybridization to oligonucleotides, washing, extension, ligation, amplification by PCR and hybridization to the Beadplate in an appropriate hybridization buffer. Image intensities were scanned by the BeadXpress Reader, and genotyped using the GenomeStudio software (Illumina). The genotype quality score for retaining data was set to 0.25. A total of 17 SNPs were successfully genotyped.
Statistics
SNP genotype frequencies were examined for Hardy--Weinberg equilibrium using the w 2 -statistic, and all were found to be consistent (P40.05) with the Hardy--Weinberg equilibrium among Korean controls. Data were analyzed using unconditional logistic repression to calculate an odds ratio (OR) as an estimate of relative risk of prostate cancer associated with SNP genotypes. 18 To determine the association between the genotype and haplotype distributions of patients and controls, logistic regression analysis was carried out controlling for age (continuous value) as covariate to eliminate or reduce any confounding that might influence the interpretation of findings. The significant associations are shown in bold face (Pp0.05). Multiple comparisons were also accounted for by using permutations to calculate exact P-values for each significant individual SNP (a ¼ 0.05). Lewontin's D 0 (|D 0 |) and the LD coefficient r 2 were examined to measure the LD between all pairs of biallelic loci. 19 Using PHASE algorithm version 2.0, 20 the haplotypes were inferred from the successfully genotyped SNPs and association analysis was performed using SAS version 9.1 (SAS, Cary, NC, USA). To correct for multiple testing of markers representing SNPs in LD with each other, the effective number of independent marker loci in HPN was calculated using SNPSpD software (http://genepi.qimr.edu.au/ general/daleN/SNPSpD/), a program that is based on the spectral decomposition of matrices of pairwise LD among markers. 21 In analyzing a model in which a codominant effect of the variant (V) allele was assumed, the genotypes wild type (W)/W, W/V and V/V were coded as 0, 1 and 2, respectively. When a dominant effect was assumed, genotype W/W was coded as 0, whereas W/V and V/V were combined and coded as 1. Accordingly, W/W and W/V were combined and scored as 0, and V/V was scored as 1 in a model that assumed a recessive effect. 22 
RESULTS
A total of 17 sequence variants in the HPN gene were examined in this study: 14 were located in introns, 1 was in the coding regions of an exon and 2 were located in the 3 0 -untranslated region (Figure 2) . Pairwise comparisons among all 17 polymorphisms revealed two sets of markers in absolute LD with each other (|D 0 | ¼ 1 and r 2 ¼ 1, Figure 2 ). The minor allele frequencies of the 17 genotyped polymorphisms are shown in Figure 2 . No significant deviations from the Hardy--Weinberg equilibrium were observed in the polymorphisms (P40.05; Supplementary Table 1) .
The genotype frequencies for each polymorphism in both the prostate cancer group and the control group were analyzed using a logistic regression model (Table 2 ). Among the 17 polymorphisms examined, 1 polymorphism, which was located in exon 6 (rs45512696), was found to be significantly associated with prostate cancer susceptibility. The frequency of the T allele of rs45512696 was significantly higher among the prostate cancer patients compared with the control group (OR ¼ 2.22, frequency ¼ 0.046 vs 0.022; P ¼ 0.04). Two SNPs (rs2305745 and rs2305747) exhibited a significant protective effect against prostate cancer in the codominant model (OR ¼ 0.73, P ¼ 0.03; OR ¼ 0.76, P ¼ 0.05, respectively; Table 2 ). There was no statistically significant association between the presence of prostate cancer and the other 14 SNPs.
In an analysis involving only the prostate cancer patients, two SNPs (rs1042328 and rs1688029) exhibited a significant protective effect against progression potential from stage criteria in the dominant model (OR ¼ 0.57, P ¼ 0.04 for both; Table 3 ); one SNP (rs870379) exhibited a similar effect in the codominant model (OR ¼ 0.69, P ¼ 0.05; Table 4 ).
DISCUSSION
The HPN gene is a potential candidate involved in prostate cancer susceptibility. It encodes a transmembrane serine protease that is overexpressed in cancerous prostate tissue, 23 particularly in the aggressive form of the cancer. 11, 24 HPN is located in 19q11--13.2, where linkage was found with prostate tumor aggressiveness. 12, 13, 25 The present case--control study was undertaken to investigate the potential association between HPN gene polymorphisms and the development of prostate cancer in a Korean study population. In this study, logistic regression analyses suggested that some HPN gene polymorphisms were associated with a significantly elevated risk of prostate cancer when compared with BPH controls. These results suggest that HPN gene polymorphisms may alter susceptibility to prostate cancer and may possibly be used as biomarkers for the disease.
There are a few reports regarding the relationship between HPN gene polymorphisms and the development of prostate cancer. Associations between the development of prostate cancer and polymorphisms in the HPN gene have been reported among populations of Caucasian ancestry; three recent publications have reported an association between variants of the HPN gene and the risk of prostate cancer, although there were minor inconsistencies among the results. 14,26,27 Pal et al. 14 genotyped 11 SNPs in the HPN gene, spanning B26 kb, which had been selected from the NCBI database (http://www.ncbi.nlm.nih.gov/) based on SNP location, validity status and heterozygosity. Holt et al. 27 took a tag SNP approach for a 36-kb region that included 5 kb upstream and downstream of the HPN gene. Abbreviations: AA, amino acid; CI, confidence interval; HPN, HEPSIN gene; MAF, mean allele frequency; OR, odds ratio; UTR, untranslated region. MAF and P-values for logistic analyses of three alternative models (co-dominant, dominant and recessive models) controlling for age as covariate are shown. Significant associations are shown in bold face (P-value p0.05).
Consistent with the results of this study, Pal et al. 14 reported that rs2305745 and rs2305747 were associated with prostate cancer risk in European patients (0.243 vs 0.292 and 0.241 vs 0.293 for mean allele frequency in cases and controls, respectively). However, Holt et al. 27 found rs2305747 was not associated with prostate cancer risk in Caucasians or African Americans. The discrepancy between these findings could be due to the different populations studied in these reports; rs45512696, which was found to be significantly associated with the risk of prostate cancer in our study (OR ¼ 2.22, 95% CI ¼ 1.02--4.81, P ¼ 0.04), was not included in the studies of Pal et al.
14 and Holt et al. 27 The study by Burmester et al. 26 found significant differences in allele frequencies between the case and control groups at rs1688030; however, we did not observe a significant association between rs1688030 and the development of prostate cancer. Haplotype analyses have shown that a major haplotype spanning all 17 SNPs was not significantly associated with prostate cancer susceptibility.
Interestingly, we observed a significant relationship between rs870379 and patient Gleason score category; classified as low (2--6), moderate (7; 3 þ 4 or 4þ 3) and high (8--10) . The data showed that the frequency of the 'major' allele was significantly higher among those patients with a high Gleason score, compared with those with a low Gleason score (Table 4) . Although it would be premature to draw definitive conclusions based on a single marker association, it is plausible that the 'minor' allele at this SNP may act as a 'protective allele' against the histological aggressiveness of prostate cancer. We also found the statistical significance in our study disappear, if we corrected multiple comparisons. However, the results of our study may be helpful in understanding the function of polymorphisms in HPN in prostate cancer development and lead to the production of prostate cancer drugs based on genetics. Further studies will be needed in this regard.
Some limitations of this study should be acknowledged. Our analysis was based on comparison of samples from patients with prostate cancer, and samples from patients with non-malignant BPH. This comparison might be somewhat different from the comparison with the general population of men without any prostatic disease. Furthermore, all the men in the BPH group are potentially at risk for development of prostate cancer and may have latent prostate cancer at time of designation as controls, leading to disease misclassification. One Korean study provides us a useful statistic. The authors evaluated cancer detection rate between patients who underwent transrectal ultrasonography biopsy before TURP (group A) and those who did not (group B). 28 The cancer detection rate of two groups was 8.9% and 7.5%, respectively. This study demonstrated the percent of Korean men incidentally detected with prostate cancer after initial diagnosis with BPH.
In summary, our study has provided evidence of an association between HPN sequence variants and prostate cancer development in a Korean study population. Further works is necessary to establish the association in other populations as well as Korean population. 
